Abstract
Sitagliptin is a dipeptidyl peptidase-4 inhibitor commonly used in the treatment of type 2 diabetes mellitus for glycaemic control. Concerns have arisen regarding adverse events caused by this drug, particularly concerning arthralgias. Here, we report on a 56-year- old man being treated with sitagliptin who developed inflammatory arthritis after taking the drug for 6 months. The patient presented with pain, swelling and erythema in multiple joints and was eventually diagnosed with seronegative rheumatoid arthritis (RA) under the 2010 American College of Rheumatology/ European League Against Rheumatism classification criteria. His symptoms continued for several months after stopping sitagliptin and eventually went into remission after a tapered course of steroids, hydroxychloroquine and methotrexate. Furthermore, the patient is HLA-DRB3 positive, a genetic marker that is still being investigated for its role in the pathogenesis of RA and that may have been a predisposing factor in the development of this patient's inflammatory arthropathy.
| Original language | English |
|---|---|
| Pages (from-to) | 12-15 |
| Number of pages | 4 |
| Journal | Drug and Therapeutics Bulletin |
| Volume | 58 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2020 |
Bibliographical note
Publisher Copyright:© Author(s) (or their employer(s)) 2020.
ASJC Scopus Subject Areas
- Pharmacology (medical)
Keywords
- drugs: Endocrine system
- immunology
- musculoskeletal and joint disorders
- rheumatoid arthritis
- unwanted effects/adverse reactions